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Abstract
Background: Antiangiogenic therapy has proved to be an important therapeutic tool for many retinal vascular
diseases; however, its availability is limited in developing countries. This study sought to describe the bevacizumab
vial sharing process and to evaluate the impact of this repackaging system on the costs incurred in a Brazilian
public hospital.
Method: This retrospective study compared the number and costs of intravitreal antiangiogenic injections
approved via court order in the first year of the study (2015) to the number and costs of the bevacizumab
injections provided through the use of vial sharing in the second year of the study (2016).
Vial sharing consists of the traditional process used to repackage bevacizumab; in this case, however, the drug
samples used were the residual volume from the preparation of bevacizumab for oncology patients. The hospital
adhered to the guidelines established by the Brazilian Health Surveillance Agency (ANVISA).
Results: In the first year of the study and using medication obtained through court orders, 550 intravitreal
injections were performed in the ophthalmology ambulatory care center. Based on local pricing tables, the total
cost of the medication was BRL$1,036,056.25 (USD$267,546.58), and the average cost of each application was
BRL$1883.74 (USD$486.45).
In the second year of the study, 1081 intravitreal applications were performed at the same hospital using doses
obtained through bevacizumab vial sharing. The total cost was BRL$21,942.49 (USD$5663.30) and the per-unit cost
was BRL$20.30, or USD$5.23 (a savings of 97.88%).
Conclusion: This study found that bevacizumab vial sharing led to a significant reduction in public health care
costs associated with antiangiogenic treatment and increased the availability of the drug to public health care
patients. These results can be extrapolated to other types of drugs and health care systems.
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Background
Since being introduced on the market, anti-vascular
endothelial growth factor (anti-VEGF) drugs, also known
as antiangiogenics, have become widely used as the
treatment of choice for retinal diseases such as diabetic
macular edema and wet age-related macular degener-
ation (wet ARMD), both of which are frequent causes of
blindness in many populations [1, 2]. In Brazil, three
antiangiogenics are available for the treatment of retinal
vascular diseases: ranibizumab (Lucentis®), aflibercept
(Eylia®), and bevacizumab (Avastin®), the last of which is
used off label in ophthalmology [3].
In Latin America, there are many obstacles to obtaining
anti-VEGF therapy. These barriers include the high cost
of care, the refusal by both private and public health care
providers to cover these medications, and patients’ limited
access to retina specialists [4]. According to 2013 data
from the Brazilian Institute of Geography and Statistics
(IBGE), 27.9% of the Brazilian population is covered by a
private health care plan; the vast majority of the
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population relies on the Brazilian National Public Health
Care System (SUS) for medical care [5]. Even in regions
where treatment from SUS or private health care plans is
available, access to medication is hindered by bureaucracy.
Patients—particularly those with limited mobility or with-
out access to reliable transportation—tend to give up on
trying to obtain anti-VEGF therapy or, when they are fi-
nally able to receive care, are no longer within their treat-
ment window. This situation reflects the importance of
improving access to effective interventions [4].
Bevacizumab is a humanized monoclonal anti-VEGF anti-
body that was originally developed and approved to treat
colorectal cancer [6]. It has not been approved for intravit-
real use by Brazilian health agencies; however, after careful
analysis of the evidence available, which has demonstrated
its safety and efficacy at rates comparable to those of other
anti-VEGF agents [7–12], the Brazilian Ministry of Health
issued an official opinion recommending this use [13–15].
In addition to the similarities between bevacizumab
and the other anti-VEGF drugs in their efficacy against
retinal diseases, an important advantage is the lower cost
of the former medication [1–3, 7]. The per-patient cost
of bevacizumab may be four to forty times lower, de-
pending on the dosages in which bevacizumab is repack-
aged [8–12]. The cost-effectiveness provided to patients
has also been proven to be higher than that provided by
ranibizumab or aflibercept [12]. Bevacizumab has been
repackaged for intravitreal injection by compounding
the drug into vials for multiple patients in an attempt to
reduce the cost of treatment while complying with the
guidelines established by the Brazilian Health Surveil-
lance Agency (ANVISA) [16].
Despite efforts in the field of oncology to reduce the
amount of leftover medication, waste cannot be com-
pletely avoided due to the fact that bevacizumab doses
depend on patient weight [6]. In the case of bevacizu-
mab, vial sharing consists of the same compounding
process outlined in Brazil’s ANVISA guidelines [16],
though with the use of quantities of the drug left over
from compounding processes performed on bevacizu-
mab doses destined for oncology patients. These leftover
quantities are repackaged for intravitreal use in an at-
tempt to reduce costs, increase the availability of antian-
giogenics for ophthalmologic treatment, and provide
patients with the same level of care while reducing waste
in the public health care system. The benefits found in
this study reflect the importance of health care policies
that support the repackaging of medications and encour-
age the least wasteful use of public resources.
Methods
Objective
To calculate the reduction in costs per patient treated
with intravitreal anti-VEGF and to demonstrate a
bevacizumab repackaging model as a viable and more ef-
fective option for public health care systems in the treat-
ment of retinal diseases such as diabetic macular edema,
ARMD, and retinal vein occlusions. To compare the dir-
ect costs of antiangiogenics used in the ophthalmology
ambulatory care center of the Clinical Hospital of the
State University of Campinas (UNICAMP) before the
implementation of this shared repackaging system to the
costs to the department after its introduction.
Study design
This was a technical, observational, and retrospective
study performed in the Retinal Ambulatory Care Center
of the Clinical Hospital of the State University of Campi-
nas (HC-UNICAMP). This hospital is part of Brazil’s
public health care system (SUS), in which many patients
must obtain a court order to receive anti-VEGF intravit-
real injection treatment.
Study subjects
The subjects included in this study were patients from
the Retinal Ambulatory Care Center of HC-UNICAMP
who received the intravitreal injection of an anti-VEGF
drug between August 2015 and July 2017 due to their
low visual acuity associated with macular abnormalities
or thickness as determined by both macular optical co-
herence tomography (OCT) and an ophthalmologic
examination, and secondary to at least one retinal dis-
ease (diabetic macular edema, macular edema secondary
to retinal vein occlusion, or wet ARMD). These patients
were transferred from regional health care departments
or sought care from HC-UNICAMP on their own ac-
cord. They were selected because they represented the
population that depends exclusively on public health
care services in the city of Campinas.
The perspective used in this study is classified as one
of a third-party payer system, which represents the Bra-
zilian National Public Health Care System (SUS); in this
system, costs associated with factors such as missed days
of work and transportation are not included and are the
patient’s responsibility [17].
The inclusion criteria in this study are consistent with
the criteria used in the protocol at the study institution
for indicating treatment with anti-VEGF drugs. The cri-
teria for each specific vascular condition are as follows:
Wet ARMD
 Active neovascular membrane on the retina
(evaluated using fundus biomicroscopy, OCT, and
angiography with fluorescein);
 No fibrous components in or around the lesion;
 No atrophy of the external retinal layers in or
around the lesion as determined by OCT;
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 Corrected visual acuity between 20/40 and 20/400 as
per the ETDRS chart and justified by wet ARMD;
Macular edema secondary to retinal vein occlusion
 Presence of intraretinal cysts or subretinal fluid in
the macular area;
 Central thickness ≥ 250 μm;
 External retinal layers intact;
 Corrected visual acuity between 20/30 and 20/200 as
per the ETDRS chart;
 Less than 1 year of progression/development;
Diabetic macular edema
 Diabetic macular edema with central involvement
 Corrected visual acuity < 20/30 as per the ETDRS
chart and due to EMD
 foveal thickness > 250 μm as per OCT
Study procedure
Patient information was obtained through data collec-
tion from patient medical records and appointments at
the local retinal ambulatory care center for the intravit-
real application of an anti-VEGF agent between August
2015 and July 2017. An analytical scope of 2 years was
selected because it provided 1 year of traditional treat-
ment that could be compared to 1 year of treatment
provided after the study intervention and because it
reflected sufficient time for a comparative analysis.
To better analyze the differences between the patients
treated in the 2 years of the study in terms of costs and
availability of the intravitreal antiangiogenic injections,
this study evaluated the number of patients, the medica-
tions used (bevacizumab, ranibizumab, and aflibercept),
and the costs associated with intravitreal injections ap-
proved via court order between August 2015 and July
2016 (the first year of the study). This study also com-
pared the number of patients treated with intravitreal in-
jections and the costs of bevacizumab in cases of vial
sharing, which was implemented from August 2016 to
July 2017 (the second year of the study).
Because the prices were provided retrospectively, they
come from different sources and years; neither source
considered prices for longer than a one-year period, and
because the long-term benefits associated with this treat-
ment were not considered herein, the concept of a dis-
count rate is not relevant to this study [17].
The study relied on primary research; the data collec-
tion process is described below and generated its own
set of quantitative information. The reference cost of
each medication obtained via court order in the first
year of the study was based on the pricing tables for
drugs sold to the Brazilian government (known locally as
the PMVG) as published by the Brazilian Department of
Drug Market Regulations (CMED) [18]. The retail price
of bevacizumab used in the second year of the study,
during which time the medication was obtained directly
from the hospital in question, was provided by study site
administrators. Because the study drug would have been
discarded, there was no opportunity cost associated with
the use of the drug; however, the costs of the profes-
sionals and physical space involved in the repackaging
process have been included.
The data obtained were organized in an Excel spread-
sheet and descriptively analyzed. The exchange rate used
for the Brazilian real (BRL) to the US dollar (USD) was
the average exchange rate of the dollar in July 2018
(3.8745 Brazilian reais to the US dollar) [19].
Ethical considerations
The study was approved by the local Research Ethics
Committee CEP (Comitê de Ética em Pesquisa) under
committee registry number CAAE (Certificado de Apre-
sentação para Apreciação Ética) 60,695,516.1.0000.5404.
This study received no outside funding and has no con-
flicts of interest. This study received assistance in the
form of information provided by the oncology pharmacy
of HC-UNICAMP, which served as a non-monetary
form of support.
Due to its classification as retrospective and observa-
tional, this study was not required to follow the guidelines
of a population study, or to obtain informed consent
forms from patients.
Bevacizumab repackaging
In health care centers, repackaging (or compounding) is
a procedure led by pharmacists. It consists of removing
a given infused drug from its original packaging and div-
iding it into smaller doses in smaller vials in a way that
maintains its quality and identifying information. In the
hospital pharmacy in this study, bevacizumab is repack-
aged in a class II B2 biological safety cabinet according
to guidelines established by ANVISA [16].
ANVISA has also established rules and regulations
regarding the compounding, storage, transportation,
and distribution of medications. These rules and regu-
lations also outline minimum prerequisites for a given
institution to perform these processes. The prerequi-
sites, with which the local hospital complies, outline
the need for common areas, a room for cleaning and
sterilizing products, a weighing area, a cleanroom ex-
clusively for compounding and container closure, a re-
view area, an area for quarantine, labeling, and
packaging, and the use of exclusive locker rooms (chan-
ging rooms) by employees. As per these guidelines, the
clean room used to compound and close sterile prepa-
rations must be separate and used exclusively for this
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purpose. It must contain air filters to retain particles
and microorganisms and to guarantee recommended
air quality as per ISO Class 5 (100 particles / ft3 of air)
or a biological safety cabinet in accordance with ISO
Class 5; it must be in an area consistent with ISO Class
7, and it must exhibit positive pressure [16].
Vial sharing consists of this same process used to re-
package bevacizumab; in this study, the quantities of the
drug used were those that were left over from the prepar-
ation of bevacizumab for oncology patients. This excess
volume was aspirated and repackaged in a biological safety
cabinet. The product was labeled and stored at adequate
temperatures levels (between 2 °C and 8 °C) to ensure the
safe transportation of the medication to the ophthalmol-
ogy ambulatory care center where the intravitreal injection
was performed with proper antiseptic care prior to injec-
tion. The vial sharing process was performed using ultra-
fine (0.03ml) syringe-needle combinations with no dead
volume. With 1ml of the drug, approximately 20 doses
for intravitreal use (1.25mg / 0.05ml per patient) were
produced per week.
Results
In the first year of the study and using medication ob-
tained through court orders, 550 intravitreal injections
were performed in the ophthalmology ambulatory care
center of the study site (192 of which were bevacizu-
mab, 347 of which were ranibizumab, and 11 of which
were aflibercept). Based on local pricing tables [18], the
total cost of the medication was BRL$1,036,056.25
(USD$267,546.58), and the average cost of each appli-
cation was BRL$1883.74 (USD$486.45). Details are pre-
sented in Table 1.
In the second year of the study, 1081 intravitreal appli-
cations were performed at the same hospital using doses
obtained through bevacizumab vial sharing, with an iso-
lated cost of BRL$17,455.98 (USD$4514.28). Given the
fact that approximately 1 hour is required to repackage
20 doses (and that doses are administered weekly), the
additional cost for the specialized medical professional
must be included (BRL$38.47 as reported in the wage
table for the study institution [20]), as well as the per-
hour cost of reserving the cleanroom (approximately
BRL$55.00 as charged by the UNICAMP Department of
Biomedical Engineering). Therefore, the total cost of vial
sharing in the second year of the study was BRL$21,
942.49 (USD$5663.30), and the per-unit cost was
BRL$20.30 (USD$5.23).
The comparison between the first and second year
revealed a 97.88% reduction (BRL$1,014,113.26, or
USD$261,740.55) in the total cost of a year of injections,
as well as a 96.54% increase in the number of injections
performed after bevacizumab vial sharing was imple-
mented. The analysis of the savings from the use of
bevacizumab rather than the currently approved antian-
giogenics if the treatment had been carried out in the 2
years of the study is shown in Table 2.
If repackaged bevacizumab doses had been used in the
550 injections in the first year, the cost for the year
would have been BRL$11,165.00, or USD$2881.66 (a
savings of BRL$1,014,113.76, or USD$261,740.55). Simi-
larly, if the injections approved via court order had been
continued at the same rate during the second year, the
total cost to treat the patients reached in the second year
would have been BRL$2,036,322.94 (USD$525,570.51).
However, given the fact that this study was performed
using vial sharing and small aliquots of bevacizumab that
the hospital would have otherwise been discarded, the
cost of the medication for the ophthalmology depart-
ment was nil and the savings achieved using this method
were even more pronounced.
Discussion
As this study shows, the reduction in cost through the
use of repackaging allowed for a public teaching hospital
to increase the number of intravitreal injections available
despite the limited resources provided to the Brazilian
public health care system.
In the first year of the study, 550 anti-VEGF injec-
tions were applied at the study site after patients ob-
tained court orders to receive treatment from August
2015 to July 2016. The total cost was BRL$1,036,
056.25 (USD$267,546.58). Because bevacizumab doses
obtained through vial sharing for this purpose cost
Table 1 Per-unit and total costa per medication according to government from August 2015 to June 2016
MEDICATION NUMBER OF APPLICATIONS COST (in BRL$/USD$) TOTAL COST (in BRL$/USD$)














aMaximum retail prices of drugs sold to the Brazilian government (known locally as the PMVG)
Sodré et al. BMC Public Health         (2019) 19:1252 Page 4 of 8
BRL$20.30 (USD$5.23) after considering the added
cost of the physical space and personnel required for
the process, the equivalent cost to treat these same
550 patients would have been BRL$11,165.00, or
USD$2881.66 if vial sharing had been implemented or if
smaller original doses had been available. In this case, this
difference represents a 98.92% savings (BRL$1,024,891.25
or USD$264,522.19).
Bevacizumab vial sharing was implemented at the
study site in the second year of the study, and 1081 in-
travitreal injections were performed in from August
2016 to July 2017. These treatments represent a 96.54%
increase in the number of applications relative to the
year prior, when vial sharing had not been implemented.
These numbers provide evidence that, at this hospital,
the main factor limiting the number of applications in
the first year was the availability of the drug. Even with
the crucial participation of the hospital pharmacy de-
partment in the introduction of the repackaging system,
there was no need for structural or personnel changes
for its implementation.
Though antiangiogenic drugs are not considered
equivalent, if an ophthalmology department within Bra-
zil’s public health care system provides only one high-
cost medication free of charge to patients, patients that
do not respond to that specific treatment are required to
request different medications through court order. As of
mid-2016, however, Brazil found itself at the peak of one
of its worst financial crises in its history. For this reason,
approval processes of court orders for high-cost medica-
tions became even more drawn out, and approvals were
not certain. The extreme scarcity of government-pro-
vided antiangiogenic drugs was the main reason that this
new method was created, since physicians needed to
provide their patients with these high-cost medications
and public hospitals wanted to make good use of the
limited supply. Because repackaged bevacizumab became
the only way to make anti-VEGF drugs available at this
institution, only this treatment was used in the second
year of the study. In the second year, cases of refractory
cystoid macular edema, for example, were treated with
triamcinolone or macular grid laser photocoagulation
(alternative therapies available in the department). In
any case, only anti-VEGF drug therapy was considered
in this study.
The cost of bevacizumab was maintained in the calcu-
lations in the second year of this study: though the doses
used were obtained from excess quantities of the drug
that would have otherwise been destroyed, the acquisi-
tion of the drug produced administrative costs for the
State Health Secretariat. In light of this situation, it can
also be argued that the cost of the drug became negli-
gible for the ophthalmology department.
This situation also reflects one of the most important
points of this study: if vial sharing processes such as
these are implemented, anti-VEGF treatment can be-
come available in hospitals and health care centers
where even traditional repackaging is not financially vi-
able. These results therefore highlight the fact that vial
sharing procedures for high-cost medications represent
a useful option for centers facing financial constraints.
It is also important to note that, by providing com-
pounded doses of the medication, the study site was able
to reduce the amount of time between indication and
the start of treatment, in addition to avoiding the admin-
istrative costs associated with court orders.
High-cost medication waste is not only a problem
in Brazil. Even when hospitals and health care sys-
tems prioritize efforts to avoid wasting infused drugs,
wasted volumes may vary between 1 and 33%. Bevaci-
zumab waste in the United States in 2016 was esti-
mated at 9% [21].
Chen et al. analyzed the sterility, stability, and efficacy
of bevacizumab repackaged into multiple doses. Their
results demonstrate that, if proper antiseptic precautions
are taken during the manipulation and use of this medi-
cation (and if the drug is stored at 4 °C for no more than
6 months), compounded doses of bevacizumab will re-
main sterile and anti-VEGF activity will remain minim-
ally (less than 10%) degraded during this period [22].
Another challenge to the implementation of this medi-
cation is the approval of bevacizumab for ophthalmo-
logic pathologies in Brazil. Despite the Ministry of
Health’s interim approval of bevacizumab for ophthal-
mologic use in the country in 2016 [13], the ROCHE® la-
boratory issued an official statement to report that it
does not agree with the temporary authorization of the
use of the drug for off-label treatment in eyes. The com-
pany believes that such off-label usage should be the sole
responsibility of patients and professionals who accept
the potential risks that have been associated with this
treatment procedure [23]. This corporate position limits
the ophthalmological use of this medication to institu-
tions that, like this one, perform scientific studies on the
Table 2 Savings if the treatment had been carried out in the 2 years of the study
1631 BEVACIZUMAB VIAL SHARING COST DIFFERENCE
1631 Bevacizumab PMVG BRL$2,106,991.04 USD$543,808.02 BRL$33,109.30 USD$8545.43 BRL$2,073,881.74 USD$535,264.35
1631 Ranibizumab PMVG BRL$3,550,230.32 USD$916,295.80 BRL$33,109.30 USD$8545.43 BRL$3,517,121,02 USD$907,761.26
1631 Aflibercept PMVG BRL$4,848,685.73 USD$1,251,433.68 BRL$33,109.30 USD$8545.43 BRL$4,815,576.43 USD$1,242,889.77
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drug. Patients must be informed of the situation and
must sign consent forms acknowledging the experimen-
tal nature of the treatment and potential risks of using
this medication in their eyes.
In Brazil, the resources allocated to public health are
insufficient and poorly managed. Brazil is a developing
country that has experienced both demographic transi-
tions and economic crises in recent years, both of which
have had substantial impacts on public health [24]. The
resources available must therefore be used economically,
particularly in cases of high-cost medications [25]. A
compounding factor in this situation is that ARMD is
considered the main cause of legal blindness among
those over 50 years of age in some industrialized nations
[26, 27]. Furthermore, researchers estimate that the glo-
bal prevalence of diabetes mellitus will increase from
2.8% (171 million) as of the year 2000 to 4.4% (366 mil-
lion) by 2030, with the most significant increases in de-
veloping countries [28–30].
According to the Brazilian National Committee for
Health Technology Incorporation (CONITEC), the
budgetary impact for treating wet ARMD in the general
population in the country in 5 years will be BRL$300,
949,504.64 (USD$77,674,410.80) in the case of ranibizu-
mab and BRL$50,236,922.63 (USD$12,966,040.17) in the
case of bevacizumab (considering repackaging into four
doses from each 0.3 ml vial of ranibizumab and 40 doses
from each 4ml vial of bevacizumab) [14].
In the case of treatment for diabetic macular edema,
CONITEC has also estimated that the use of repackaging
in this situation would result in a three-year budgetary im-
pact ranging from BRL$143,002,198.00 or USD$36,908,
555.43 (if repackaged bevacizumab were used) to BRL$12,
359,563,100.00 or USD$3,189,976,280.81 (if single-dose
vials of ranibizumab were used) [15].
Assuming the difference in cost identified by CONI-
TEC for the use of repackaged bevacizumab rather than
ranibizumab (four doses in the treatment of ARMD or a
single dose in the treatment of diabetic macular edema),
if repackaged bevacizumab were used in the Brazilian
public health care system at the repackaged dose value
found in this study (BRL$20.30 or USD$5.23), the gov-
ernment would be able to provide 12,350,376.49 doses
for the treatment of wet ARMD at 5 years and 601,801,
029.65 doses for diabetic macular edema at 3 years.
It is important to note that CONITEC does not
consider the costs of the repackaging process in its as-
sessment of the economic impact of repackaging bevaci-
zumab using the methods performed in this study. The
cost of vial sharing may be financially viable due to the
substantial savings provided by the use of this drug in
this way.
The cost of the syringe is also negligible relative to the
possible savings provided by the use of this medication,
in part because the syringes used in the repackaging
process are also used in the application of the drug. The
cost of follow-up care was not considered, since this care
is provided regardless of the medication used.
The Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) statement was developed
by a task force as part of a broader initiative to facilitate
and encourage economic assessments in health care;
however, because the current study included a simple
economic analysis without a consequence analysis or a
consideration of health-related outcomes, some items of
the CHEERS protocol do not apply to this study [31].
Other limitations of our study are its retrospective na-
ture, the need for a specifically structured hospital phar-
macy, and the training required for pharmaceutical
professionals in order for the hospital to comply with
the rules of the local health surveillance agency.
Conclusion
This study provides a model for the repackaging of beva-
cizumab through a vial sharing process as a viable option
for public hospitals. In Brazil, this process complies with
Brazilian Health Surveillance Agency (ANVISA) regula-
tions and has been found to increase availability and re-
duce the cost of treatment for diseases such as diabetic
macular edema, age-related macular degeneration, and
retinal vein occlusions. In the comparison between the
first year of the study (when treatment was available to
patients only through a court order) and the second year
of the study (when repackaging via vial sharing was im-
plemented), the use of compounded doses of bevacizu-
mab resulted in a 97.88% savings on drug costs and a
96.54% increase in the availability of treatment, as well
as a reduction in wasted aliquots.
The increased number of patients treated and the re-
duction in costs represent the benefits provided to the
public health care system and patients alike. Due to the
promising results of this study, further research and ana-
lysis are encouraged to evaluate the effects of repack-
aging of high-cost medications and of other measures on
the efficient use of public resources.
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